Cargando…

Primary and Acquired Resistance against Immune Check Inhibitors in Non-Small Cell Lung Cancer

SIMPLE SUMMARY: NSCLC accounts for approximately 84% of lung malignancies and the clinical application of ICIs provides a novel and promising strategy. However, approximately 80% of NSCLC patients do not benefit from ICIs due to drug resistance complicated by disciplines and diverse mechanisms. Thro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Qinying, Wei, Xiangzhen, Wang, Zhonglin, Zhu, Yan, Zhao, Weiying, Dong, Yuchao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9316464/ https://www.ncbi.nlm.nih.gov/pubmed/35884355 http://dx.doi.org/10.3390/cancers14143294

Ejemplares similares

Immune Check Point Inhibitors and Immune-Related Adverse Events in Small Cell Lung Cancer
por: Hou, Wanting, et al.
Publicado: (2021)

The toxicity associated with combining immune check point inhibitors with tyrosine kinase inhibitors in patients with non-small cell lung cancer
por: Kalra, Anjali, et al.
Publicado: (2023)

Clinical pattern of failure after a durable response to immune check inhibitors in non-small cell lung cancer patients
por: Heo, Ja Yoon, et al.
Publicado: (2021)

Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib
por: Kim, Seulki, et al.
Publicado: (2019)

CheckMate 227 trial has not checked the immune-strategy in first-line setting in advanced non-small cell lung cancer
por: Remon, Jordi, et al.
Publicado: (2020)

Immune Check Point Inhibitors Triggering Non Autoimmune Polyendocrinopathy
por: Vergne-Santiago, Norma, et al.
Publicado: (2021)

Nogo-B protects mice against lipopolysaccharide-induced acute lung injury
por: Xu, Wujian, et al.
Publicado: (2015)

Immune Check Point Inhibitor–Associated Glomerulonephritis
por: Ashour, Tarek, et al.
Publicado: (2018)

Immune Check Point Inhibitor–Associated Endothelialitis
por: Bobart, Shane A., et al.
Publicado: (2020)

Mechanisms of Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Patients with Hepatocellular Carcinoma
por: De Lorenzo, Stefania, et al.
Publicado: (2022)

ERK inhibitor ASN007 effectively overcomes acquired resistance to EGFR inhibitor in non‐small cell lung cancer
por: Ku, Bo Mi, et al.
Publicado: (2022)

An Analysis of BMP1 Associated with m6A Modification and Immune Infiltration in Pancancer
por: Zhou, Yiyi, et al.
Publicado: (2022)

The impact of PD-L1 on survival and value of the immune check point inhibitors in non-small-cell lung cancer; proposal, policies and perspective
por: Guirgis, Helmy M.
Publicado: (2018)

The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancer
por: Bredin, Philip, et al.
Publicado: (2022)

RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer
por: Wang, Chunyue, et al.
Publicado: (2022)

Autocrine EGF and TGF‐α promote primary and acquired resistance to ALK/c‐Met kinase inhibitors in non‐small‐cell lung cancer
por: Wang, Yueqin, et al.
Publicado: (2022)

Factors Predictive of Primary Resistance to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer
por: Huang, Yiqing, et al.
Publicado: (2023)

Editorial: Primary and acquired resistance in lung cancer
por: Bruno, Rossella, et al.
Publicado: (2023)

Clinical strategies for acquired epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small-cell lung cancer patients
por: Dong, Lijun, et al.
Publicado: (2017)

Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance
por: Santoni-Rugiu, Eric, et al.
Publicado: (2019)

Resistance to immune checkpoint inhibitors in KRAS-mutant non-small cell lung cancer
por: Li, Yunchang, et al.
Publicado: (2022)

Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer
por: Zhou, Kexun, et al.
Publicado: (2023)

Targeting the Golgi apparatus to overcome acquired resistance of non-small cell lung cancer cells to EGFR tyrosine kinase inhibitors
por: Ohashi, Yoshimi, et al.
Publicado: (2017)

Different interpretations of the CheckMate-227 trial in non-small-cell lung cancer
por: Su, Zheng
Publicado: (2020)

Recent advances in primary resistance mechanisms against immune checkpoint inhibitors
por: Li, Yi-Ze, et al.
Publicado: (2022)

Ovarian Cancer Treatments Strategy: Focus on PARP Inhibitors and Immune Check Point Inhibitors
por: Nero, Camilla, et al.
Publicado: (2021)

Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer
por: Suda, Kenichi, et al.
Publicado: (2015)

Immune Check Point Inhibitors in Primary Cutaneous T-Cell Lymphomas: Biologic Rationale, Clinical Results and Future Perspectives
por: Roccuzzo, Gabriele, et al.
Publicado: (2021)

Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer
por: Guo, Renhua, et al.
Publicado: (2011)

CDK4/6 inhibitor palbociclib overcomes acquired resistance to third‐generation EGFR inhibitor osimertinib in non‐small cell lung cancer (NSCLC)
por: Qin, Qiong, et al.
Publicado: (2020)

Targeted therapy of ovarian cancer including immune check point inhibitor
por: Kim, Jin Young, et al.
Publicado: (2017)

SAT-239 Combination of Immune Check Point Inhibitors Causing Hypopituitarism
por: Dhillon, Puneet, et al.
Publicado: (2020)

Acquired small cell lung cancer resistance to Chk1 inhibitors involves Wee1 up‐regulation
por: Zhao, Xiaoliang, et al.
Publicado: (2021)

ALK rearrangements as mechanisms of acquired resistance to osimertinib in EGFR mutant non‐small cell lung cancer
por: Hou, Helei, et al.
Publicado: (2021)

Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy
por: Boyero, Laura, et al.
Publicado: (2020)

Resistance to immune checkpoint inhibitors in non-small cell lung cancer: biomarkers and therapeutic strategies
por: Walsh, Robert J., et al.
Publicado: (2020)

Biomarkers of resistance to immune checkpoint inhibitors in non-small-cell lung cancer: myth or reality?
por: Pourmir, Ivan, et al.
Publicado: (2020)

Characterization of acquired nutlin-3 resistant non-small cell lung cancer cells
por: Deben, Christophe, et al.
Publicado: (2021)

ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
por: Yoshida, Takeshi, et al.
Publicado: (2016)

Usefulness of Bronchoscopic Rebiopsy of Non-Small Cell Lung Cancer with Acquired Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor
por: Goag, Eun Kyong, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_08f5r6btn49nqfgfb530ku5tkl